27722 Biologic initiation rates in psoriasis after first-line systemic use of apremilast vs methotrexate

David Kaplan, M. Elaine Husni, Eunice Chang, Michael S. Broder, Caleb Paydar, Katalin Bognar, Jessie T. Yan, Sven Richter, Pooja Desai, Ibrahim Khilfeh

Article2021

Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non‐biologic systemic therapies

K.J. Mason, A. David Burden, Juliet N. Barker, Mark Lunt, Huda Rajab Ali, C. Elise Kleyn, Kathleen McElhone, Moetaza M. Soliman, Adèle C. Green, Christopher Em Griffiths, Nick J. Reynolds, Anthony D. Ormerod

Article2020

<p>Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis</p>

David Kaplan, Brian Ung, Corey Pelletier, Chuka Udeze, Ibrahim Khilfeh, Marc Tian

Article2019

PSS6 COMPARISON OF TREATMENT SWITCHING AMONG BIOLOGIC-NAIVE PSORIASIS PATIENTS INITIATING APREMILAST OR BIOLOGIC TREATMENT: RESULTS FROM A US CLAIMS DATABASE

David Kaplan, Benjamin S.‐Y. Ung, Corey Pelletier, Chuka Udeze, M. Tian

Article2021

Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis

David Kaplan, Brian Ung, Corey Pelletier, Chuka Udeze, Ibrahim Khilfeh, Marc Tian

27722 Biologic initiation rates in psoriasis after first-line systemic use of apremilast vs methotrexate

Discussion(0)

Related publications

Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use

Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non‐biologic systemic therapies

&lt;p&gt;Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis&lt;/p&gt;

PSS6 COMPARISON OF TREATMENT SWITCHING AMONG BIOLOGIC-NAIVE PSORIASIS PATIENTS INITIATING APREMILAST OR BIOLOGIC TREATMENT: RESULTS FROM A US CLAIMS DATABASE

Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis

<p>Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis</p>